Diclazepam CAS: 2894-68-0

CAS NO: 2894-68-0
Our products are for experimental study only
Diclazepam
Chemical Name: Diclazepam
Molecular Formula: C16H12Cl2N2O
Formula Weight: 319.19
CAS No.: 2894-68-0
Description Review
Description
Our products are for experimental study only

Diclazepam is a benzodiazepine derivative that was first synthesized in the 1960s. This compound acts as a sedative-hypnotic agent and anxiolytic, similar to other benzodiazepines. The chemical name for Diclazepam is 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one. The molecular formula for this compound is C16H12Cl2N2O, and it has a molecular weight of 319.19 g/mol. The CAS number for Diclazepam is 2894-68-0.

Top Ten Keywords and Synonyms

  1. Benzodiazepine
  2. Sedative-hypnotic
  3. Anxiolytic
  4. Clonazolam
  5. Flubromazepam
  6. Etizolam
  7. Research chemical
  8. Central nervous system depressant
  9. Prescription drug
  10. Tranquilizer

Chemical Structure and Health Benefits of Diclazepam

The health benefits of Diclazepam are related to its ability to act on the central nervous system (CNS). This compound works by binding to the gamma-aminobutyric acid (GABA) receptor in the brain, which increases the inhibitory effects of GABA neurotransmitters. This leads to a decrease in neuronal activity, resulting in sedation, relaxation, and anxiety relief.

Diclazepam is commonly used in the research community as a reference standard or analytical reagent. It is not approved for medical use or as a pharmaceutical drug in most countries. However, some individuals may use Diclazepam recreationally to achieve its sedative and anxiolytic effects.

Potential Effects of Diclazepam

Diclazepam can produce a range of effects depending on the dose, route of administration, and individual factors. Some of the potential effects of this compound include:

  1. Sedation - Diclazepam can induce drowsiness and sedation, leading to decreased alertness and reaction time.
  2. Muscle Relaxation - This compound can cause muscle relaxation and relief from muscle spasms or tension.
  3. Anxiety Relief - Diclazepam can reduce feelings of anxiety, fear, and apprehension.
  4. Anticonvulsant - Diclazepam has anticonvulsant properties, meaning it can prevent or suppress seizures.
  5. Amnesia - High doses of Diclazepam can cause amnesia or memory impairment.
  6. Euphoria - Diclazepam can cause feelings of euphoria or well-being at higher doses, increasing the risk of misuse and addiction.

Product Mechanism

Diclazepam works by enhancing the effects of GABA neurotransmitters in the brain. GABA receptors are located throughout the CNS and are involved in regulating neuronal activity. When activated, GABA receptors inhibit the activity of neurons, reducing excitability and producing a calming effect. Benzodiazepines like Diclazepam bind to a specific site on the GABA receptor, increasing the affinity of GABA for the receptor and facilitating its inhibitory effects. This leads to a decrease in the firing rate of neurons, resulting in sedation, relaxation, and anxiety relief.

Safety and Side Effects

Diclazepam is not approved for medical use, and its safety profile has not been extensively studied in humans. However, like other benzodiazepines, this compound can cause side effects, especially at higher doses or with long-term use. Some of the possible side effects of Diclazepam include:

  1. Drowsiness
  2. Fatigue
  3. Impaired coordination
  4. Headache
  5. Nausea
  6. Dry mouth
  7. Confusion
  8. Memory impairment
  9. Depression
  10. Irritability

In addition, Diclazepam can be habit-forming and lead to physical dependence if used for extended periods. Abruptly stopping this medication can cause withdrawal symptoms, including anxiety, agitation, tremors, and seizures.

Dosing Information

Since Diclazepam is not approved for medical use, there is no standard dosing information available. However, some individuals may use this compound recreationally or as a research chemical. In these cases, the dosage may vary widely depending on the individual's experience, tolerance, and desired effects.

Conclusion

Diclazepam is a benzodiazepine derivative that has sedative-hypnotic and anxiolytic effects. Although it is not approved for medical use, it is sometimes used in the research community as a reference standard or analytical reagent.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code